Christopher D Byrne

79PUBLICATIONS
317CO-AUTHORS
Metabolic medicineTe ariā o ngā tauira panoni hauora o te Māori (Māori theory of change models for health)Medical infection agents (incl. prions)Molecular targetsCancer diagnosis
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (79)

|Jul 17, 2026
Characteristics and outcomes of patients with imaging-defined MASLD and histological steatosis grade S0.

|Jun 20, 2026
Burden and Regional Disparities of MASH-Related Liver Cancer in the Asia-Pacific Region From 1990 to 2023.

|May 21, 2026
MASLD prevalence, incidence and global aspects.

|Mar 14, 2026
Hepatocyte SLCO4C1 is a cAMP uptake transporter for inhibiting lipogenesis and a therapeutic target for MASLD.

Xiaojia Huang, Sen Liang, Nan Zhao

|Mar 02, 2026
Colorectal cancer in metabolic dysfunction-associated steatotic liver disease: an international Delphi consensus statement.

Chu-Tian Wu, Giovanni Targher, Christopher D Byrne

|Jan 04, 2026
Author Correction: Μetabolic dysfunction-associated steatotic liver disease: a condition of heterogeneous metabolic risk factors, mechanisms and comorbidities requiring holistic treatment.

Christopher D Byrne, Angelo Armandi, Vanessa Pellegrinelli

Pageof 14

Frequent Collaborators

44 joint publications

Giovanni Targher

23 joint publications

Minghua Zheng

9 joint publications

Seungho Ryu

9 joint publications

Herbert Tilg